Health Innovation Next Generation Payment & Pricing Models

Informazioni relative al progetto

HI-PRIX

ID dell’accordo di sovvenzione: 101095593

DOI

10.3030/101095593

Progetto chiuso

Data della firma CE 11 Novembre 2022

Data di avvio 1 Gennaio 2023

Data di completamento 31 Dicembre 2025

Finanziato da

• Health

Costo totale

€ 3 962 457,50

Contributo UE

€ 3 962 457,50

Coordinato da

UNIVERSITA COMMERCIALE LUIGI BOCCONI
Italy

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (13)

Recommendations on pricing principles for multi-indication products and conditions for their successful implementation
A novel dynamic pricing model that links to clinical benefit: impact and acceptability for stakeholders
Strength of incentive mechanisms and policy recommendations to incentivize pharmaceutical innovation in key areas of need
Equity implications of including indirect medical costs and environmental impacts in economic evaluations informing pricing and reimbursement
Policy guide on the role of cost-effectiveness and budget impact analyses (including indirect medical costs and environmental impacts) in pricing and reimbursement decisions in different European decision contexts
Outline of the equity-issues mitigation strategies identified, and related potential obstacles
Stakeholders judgement on barriers and enablers of novel payment/pricing schemes
Effectiveness and equity implications of selected pharmaceutical innovation policies and incentive mechanisms
Guidance (Handbook) on estimations (ranges) of cost elements along the value chain for demanding detailed information in price negotiations
Report on the overall performance of a selection of equity-issues mitigation strategies and recommendations
Set of recommendations for using the public investment in the negotiation/HTA process and pilot example how price can be different if public investment is considered
Policy recommendations about successful and flexible implementation of the different schemes to promote access to high-quality affordable innovative health technologies
Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on lo

Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on long-term competition in health technology markets

Demonstrators, pilots, prototypes (2)

Assessment of transferability and generalizability of results and development of a toolkit for decision-makers
Impact of applying the new payment schemes to (a) a primary care and (b) an integrated care setting

Websites, patent fillings, videos etc. (1)

Launch of project website

Pubblicazioni

Peer reviewed articles (18)

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes

Autori: Baptiste Haon, Mira Hartmann, Sanae Akodad, Hilde Stevens, Lise Rochaix
Pubblicato in: Frontiers in Medical Technology, Numero 8, 2026, ISSN 2673-3129
Editore: Frontiers Media SA
DOI: 10.3389/FMEDT.2026.1729631

Journal of Pharmaceutical Policy and Practice

Autori: Louise Schmidt; Ozren Sehic; Ursula Theuretzbacher; Daniel Fabian; Claudia Wild
Pubblicato in: Journal of Pharmaceutical Policy and Practice, 2025, ISSN 2052-3211
Editore: Taylor & Francis
DOI: 10.1080/20523211.2024.2449045

AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen

Autori: Ozren Sehic
Pubblicato in: QUALITAS, 2024, ISSN 2730-7298
Editore: Springer Nature
DOI: 10.1007/S43831-024-0187-6

Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review

Autori: Mario García-Díaz; Zuzana Špacírová; Leticia García-Mochón; Jaime Espín
Pubblicato in: Applied Health Economics and Health Policy, 2025, ISSN 2509-4254
Editore: Springer Nature
DOI: 10.1007/S40258-025-00994-5

Frontiers in Psychiatry

Autori: Sanae Akodad, Michel Goldman, Hilde Stevens
Pubblicato in: Frontiers in Medicine, Numero 12, 2025, ISSN 1664-0640
Editore: Frontiers Research Foundation
DOI: 10.3389/FMED.2025.1642882

Applied Health Economics and Health Policy

Autori: Ludovico Cavallaro; Vittoria Ardito; Michael Drummond; Oriana Ciani
Pubblicato in: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Editore: Open Mind Journals
DOI: 10.1007/S40258-025-00963-Y

Health Policy

Autori: Claudia Wild; Ozren Sehic; Louise Schmidt; Daniel Fabian
Pubblicato in: Health Policy, 2025, ISSN 0168-8510
Editore: Elsevier Ltd.
DOI: 10.1016/J.HEALTHPOL.2024.105235

Frontiers in Pharmacology

Autori: García Díaz, Mario; Epstein, David Mark; Espín, Jaime
Pubblicato in: Frontiers in Pharmacology, 2025, ISSN 1663-9812
Editore: Frontiers Media SA
DOI: 10.3389/FPHAR.2025.1670845

Social Science and Medicine

Autori: Arianna Gentilini; Marisa Miraldo
Pubblicato in: Social Science & Medicine, 2023, ISSN 0277-9536
Editore: Pergamon Press Ltd.
DOI: 10.1016/J.SOCSCIMED.2023.116332

Orphan medical devices: addressing the regulatory and access gaps in the EU and US

Autori: Sanae Akodad; Baptiste Haon; Lise Rochaix; Hilde Stevens
Pubblicato in: Frontiers in Public Health, 2026, ISSN 2296-2565
Editore: Frontiers Media SA
DOI: 10.3389/FPUBH.2025.1729821

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs

Autori: Mario García-Díaz; Jorge Mestre-Ferrándiz; Jaime Espín
Pubblicato in: PharmacoEconomics - Open, 2026, ISSN 2509-4262
Editore: Springer Nature
DOI: 10.1007/S41669-025-00628-5

PharmacoEconomics

Autori: Vittoria Ardito; Oriana Ciani; Michael Drummond
Pubblicato in: PharmacoEconomics, 2024, ISSN 1179-2027
Editore: Adis International Ltd.
DOI: 10.1007/S40273-024-01435-2

Applied Health Economics and Health Policy

Autori: Ardito, Vittoria; Banks, Helen; Tarricone, Rosanna
Pubblicato in: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Editore: Springer Nature
DOI: 10.1007/S40258-025-01010-6

Journal of Pharmaceutical Policy and Practice

Autori: Daniel Fabian; Ozren Sehic; Claudia Wild
Pubblicato in: The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions, 2025, ISSN 2052-3211
Editore: Taylor & Francis Group
DOI: 10.1080/20523211.2025.2534919

Medicare Negotiations Could Fuel, Not Stifle, Innovation.

Autori: Chuanzi Yue, Marisa Miraldo
Pubblicato in: Health Affairs Forefront, 2025, ISSN 3070-667X
Editore: Health Affairs Publishing, LLC
DOI: 10.1377/FOREFRONT.20250116.482319

A Framework for Considering the Role of the Public Sector in R&D of Health Technology

Autori: Juan Carlos Rejon-Parrilla; David Epstein; Jorge Mestre-Ferrandiz; Jaime Espin
Pubblicato in: Pharmaceutical Medicine, 2025, ISSN 0306-3747
Editore: Springer Nature
DOI: 10.1007/S40290-025-00576-9

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review

Autori: ARDITO, VITTORIA; CAVALLARO, LUDOVICO; DRUMMOND, MICHAEL; CIANI, ORIANA
Pubblicato in: PharmacoEconomics - Open, 2024, ISSN 2509-4254
Editore: Springer Nature
DOI: 10.1007/S41669-024-00496-5

ESG Performance, Debt Financing, and R&D Output: Evidence From the Healthcare Sector

Autori: Sarmad Ali; Oriana Ciani; Simone Ghislandi
Pubblicato in: Business Strategy and the Environment, ISSN 1099-0836
Editore: John Wiley & Sons Ltd
DOI: 10.1002/BSE.70522